This thesis focuses on improving HIV treatments for children in Sub-Saharan Africa, where access to suitable medication is often limited. It investigates the pharmacokinetics of dolutegravir, a key antiretroviral drug, and provides insights into developing child-friendly formulations and dosages. Using advanced modeling techniques, it refines drug dosing to better suit children's needs, considering factors like age and weight. Additionally, innovations like long-acting injections are explored to enhance adherence, which is especially crucial in low-income countries where daily medication can be challenging. The research contributes to aligning pediatric treatments with those used for adults and offers valuable insights that could improve the quality of life for children living with HIV. This work emphasizes the ongoing need for innovations in HIV care, ensuring a healthier future for children worldwide.
Lisanne Bevers (born 17 July 1997) completed her master's in Pharmacy at Utrecht University in 2021. She then began her PhD at Radboud UMC, focusing on optimising HIV treatment for children in Africa. Throughout her studies and research, Lisanne has gained international experience, volunteered in Ghana, and actively participated in academic and professional networks, blending research with clinical practice.